Thematic Investing

Featured

BUZZ Investing: Sentiment Toward Energy on the Rise

Blog | November 20

Pharma Sector Steps up as a Portfolio Prescription

Explore All

Related Funds

EVX
VanEck Environmental Services ETF

BJK
VanEck Gaming ETF

BBH
VanEck Biotech ETF

RTH
VanEck Retail ETF

SMH
VanEck Semiconductor ETF

PPH
VanEck Pharmaceutical ETF

Fund Description

VanEck Pharmaceutical ETF (PPH^®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS^®US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Fund Ticker
PPH
Exchange
NASDAQ
Inception Date
12/20/2011
ETF Structure
Physical
Administrator
Van Eck Associates
Index Ticker
MVPPHTR
Index Rebalancing
Quarterly

as of 07/01/22

30-Day SEC Yield
1.68%
Total Net Assets
$590.7M
Number of Holdings
25
Options
Available
Gross Expense Ratio²
0.35%
Net Expense Ratio/TER²
0.35%
Distribution Frequency
Quarterly
Next Distribution Date
09/30/2022

Schedule a Call

Morningstar™ Ratings³
as of 05/31/2022

Category	Overall	3 Year	5 Year
Health	3 stars of 142 funds	4 stars of 142 funds	3 stars of 132 funds

Key Points

Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume

Industry Leaders
Index methodology favors the largest companies in the industry

Global Scope
Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Trading Information

Fund Ticker
PPH
Index Total Return Ticker
MVPPHTR
NAV
PPHNV
Intraday NAV (IIV)⁴
PPHIV
Shares Outstanding
7,638,138
Estimated Cash
PPHEU
Total Cash
PPHTC
CUSIP
92189F692
ISIN
US92189F6925

Source: Bloomberg

Fees and Expenses²

Management Fee
0.35%
Other Expenses
--
Acquired Fund Fees and Expenses
--
Gross Expense Ratio
0.35%
Fee Waivers and
Expense Reimbursement
--
Net Expense Ratio/TER²
0.35%

²'Van Eck Associates Corporation (the “Adviser”) will pay all expenses of the Fund, except for the fee payment under the investment management agreement, acquired fund fees and expenses, interest expense, offering costs, trading expenses, taxes and extraordinary expenses. Notwithstanding the foregoing, the Adviser has agreed to pay the offering costs until at least February 1, 2023.'

Investment Professionals

Peter Liao, CFA

Portfolio Manager and Head of Equity ETFs
Oversees the Equity ETF Investment Management Team including development and management of index replication and optimization strategies
Joined VanEck in 2005
CFA charterholder; member of the CFA Society New York
BA, Mathematics and Economics, New York University

Guo Hua (Jason) Jin

Portfolio Manager and Analyst for Equity ETFs
Joined VanEck in 2007
Prior to his current role, held a portfolio administration position at VanEck
Previously, Portfolio Analyst at Evaluation Associates
BS, Business Administration (concentration in Financial Analysis), State University of New York at Buffalo

Griffin Driscoll

Analyst for Equity ETFs
Joined VanEck in 2018
Prior to joining VanEck, ETF Basket Operations Analyst at JPMorgan
BS, Finance, Providence College

Ralph Lasta

Analyst for Equity ETFs
Joined VanEck in 2019
Prior to VanEck, Intermediate Representative, Exchange Traded Funds at BNY Mellon.
BS, Accounting, Hunter College

Prices as of 07/01/22

	NAV/ Market Price	Volume 30-Day Avg./ Last Trading Day	Daily Change NAV/ Last Price	YTD Change NAV/ Last Price	Premium/ Discount			30-Day Median Bid Ask Spread	NAV Chart
PPH	$77.33 $77.26	214,365 180,655	$0.49 / +0.64% $0.42 / +0.55%	+1.03% +0.92%	$-0.07 -0.09%			0.03%

Premium/Discount History as of 07/01/22

		Calendar Year 2021	3Q 2021	4Q 2021	1Q 2022	2Q 2022
	Days closed at a premium	146	36	41	29	30
PPH	Days closed at NAV	24	5	8	9	7
	Days closed at a discount	82	23	15	24	25

Performance History: Average Annual Total Returns* (%)
View All ETFs View All Indices

Monthly Return

Month End as of 05/31/22
Quarter End as of 03/31/22

	1 MO	3 MO	YTD	1 YR	3 YR	5 YR	10 YR	LIFE 12/20/11
PPH (NAV)	2.10	5.15	3.49	11.71	15.14	8.61	10.27	10.07
PPH (Share Price)	2.17	5.20	3.50	11.74	15.15	8.61	10.28	10.17
MVPPHTR (Index)	2.07	5.14	3.44	11.44	14.84	8.44	10.17	9.96
Performance Differential (NAV - Index)	0.03	0.01	0.05	0.27	0.30	0.17	0.10	0.11

	1 MO	3 MO	YTD	1 YR	3 YR	5 YR	10 YR	LIFE 12/20/11
PPH (NAV)	5.24	3.58	3.58	17.62	11.51	9.66	9.80	10.25
PPH (Share Price)	5.35	3.64	3.64	17.57	11.53	9.69	9.82	10.36
MVPPHTR (Index)	5.22	3.53	3.53	17.27	11.19	9.47	9.68	10.13
Performance Differential (NAV - Index)	0.02	0.05	0.05	0.35	0.32	0.19	0.12	0.12

*Returns less than one year are not annualized.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Please call 800.826.2333 or visit vaneck.com for performance current to the most recent month ended.

The "Net Asset Value" (NAV) of a Fund is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. Investors should not expect to buy or sell shares at NAV.

Top 10 Holdings (%) as of 05/31/22 Daily Holdings

Total Holdings: 25

Swipe
to view
full data

Holding Name	Ticker	Shares	Market Value (US$)	% of Net Assets
Eli Lilly & Co	LLY US	87,288	27,359,551	5.67
Merck & Co Inc	MRK US	294,881	27,137,898	5.63
Bristol-Myers Squibb Co	BMY US	336,695	25,403,638	5.27
Novartis Ag	NVS US	279,235	25,393,631	5.27
Astrazeneca Plc	AZN US	379,600	25,235,808	5.23
Pfizer Inc	PFE US	470,544	24,957,654	5.17
Mckesson Corp	MCK US	74,663	24,540,981	5.09
Viatris Inc	VTRS US	1,990,806	24,427,190	5.06
Johnson & Johnson	JNJ US	135,444	24,316,261	5.04
Novo Nordisk A/S	NVO US	218,337	24,104,405	5.00
Top 10 Total (%)				52.43

These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 05/31/22

Country
% of Net Assets
■
United States
66.81
■
United Kingdom
9.78
■
Switzerland
5.27
■
Denmark
5.00
■
France
4.88
■
Japan
4.28
■
Israel
3.68
■
Ireland
0.22
■
Other/Cash
0.09

Sector Weightings (%) as of 05/31/22

Sector
% of Net Assets
■
Health Care
99.9
■
Other/Cash
0.1